SHENZHEN ATOMSTACK TECHNOLOGIES recalled material processing laser products on September 30, 2025, due to a missing remote interlock connector. This defect poses a high risk according to federal regulations. Consumers should stop using these devices immediately and follow manufacturer instructions for remedy.
Lack of Remote Interlock Connector - required per 21 CFR 1040.10(f)(3)
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact SHENZHEN ATOMSTACK TECHNOLOGIES or your healthcare provider for instructions. Notification method: N/A
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves material processing laser products from SHENZHEN ATOMSTACK TECHNOLOGIES. These devices were distributed in the U.S. The specific model numbers are not available.
The material processing laser products lack a remote interlock connector, which is required by 21 CFR 1040.10(f)(3). This connector is essential for safe operation and to prevent accidents.
No specific incidents or injuries have been reported regarding this recall. The absence of the required connector presents a high risk of safety hazards.
Stop using the devices immediately. Contact SHENZHEN ATOMSTACK TECHNOLOGIES or your healthcare provider for further instructions regarding the recall.
For more information, visit the FDA recall page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=Z-0888-2026.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.